These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7272965)

  • 21. Prognostic value of cytologic parameters in acute myelogenous leukemia.
    Zittoun R; Cadiou M; Bayle C; Suciu S; Solbu G; Hayat M
    Cancer; 1984 Apr; 53(7):1526-32. PubMed ID: 6582994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia.
    Herzig RH; Lazarus HM; Wolff SN; Phillips GL; Herzig GP
    J Clin Oncol; 1985 Jul; 3(7):992-7. PubMed ID: 3894588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Long-term results of the UHKT-911 study of adult patients under 65 years of age with de novo acute myeloid leukemias without favorable karyotypes].
    Lemez P; Vítek A; Michalová K; Zemanová Z; Lukásová M
    Vnitr Lek; 2003 Mar; 49(3):174-80. PubMed ID: 12728590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peripheral acute leukemia: high peripheral but low-marrow blast count.
    Cason JD; Trujillo JM; Estey EH; Huh YO; Freireich EJ; Stass SA
    Blood; 1989 Oct; 74(5):1758-61. PubMed ID: 2790200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes.
    Cheson BD; Jasperse DM; Simon R; Friedman MA
    J Clin Oncol; 1986 Dec; 4(12):1857-64. PubMed ID: 3537219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-dose cytosine arabinoside in patients with acute myeloid leukemia not eligible for standard chemotherapy.
    Pascarella A; Marrani C; Leoni F; Ciolli S; Nozzoli C; Caporale R; Salti F; Rossi Ferrini P
    Leuk Lymphoma; 1995 Aug; 18(5-6):465-9. PubMed ID: 8528054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Characteristics and Prognosis of 24 Cases of Primary Acute Myeloid Leukemia with Trisomy 8].
    Wang JH; Yao B; Guo M; Qiao JH; Sun QY; Hu KX; Li BX; Yu CL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):655-61. PubMed ID: 27342486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone marrow morphology during induction phase of therapy for acute myeloid leukemia (AML).
    Dick FR; Burns CP; Weiner GJ; Heckman KD
    Hematol Pathol; 1995; 9(2):95-106. PubMed ID: 7559259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A four-year experience with anthracycline, cytosine arabinoside, vincristine and prednisone combination chemotherapy in 325 adults with acute leukemia.
    Keating MJ; Smith TL; McCredie KB; Bodey GP; Hersh EM; Gutterman JU; Gehan E; Freireich EJ
    Cancer; 1981 Jun; 47(12):2779-88. PubMed ID: 6942906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].
    Rodríguez JN; Fernández-Jurado A; Martino ML; Diéguez JC; Moreno MV; Quesada JA; Polo B; Cañavate M; Amian A; Prados D
    Sangre (Barc); 1998 Feb; 43(1):35-9. PubMed ID: 9580427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.
    Tallman MS; Appelbaum FR; Amos D; Goldberg RS; Livingston RB; Mortimer J; Weiden PL; Thomas ED
    J Clin Oncol; 1987 Jun; 5(6):918-26. PubMed ID: 3585446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute promyelocytic leukemia is a distinct subset of acute myelocytic leukemia with unique clinicopathologic characteristics including longer duration of relapse free survival: experience in 13 cases.
    Lee KH; Kim DH; Lee JS; Suh CW; Kim SW; Kim SB; Lee JH; Doh BS; Chi HS; Lee MS
    J Korean Med Sci; 1994 Dec; 9(6):437-43. PubMed ID: 7786438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A prognostic factor analysis for use in development of predictive models for response in adult acute leukemia.
    Keating MJ; Smith TL; Gehan EA; McCredie KB; Bodey GP; Freireich EJ
    Cancer; 1982 Aug; 50(3):457-65. PubMed ID: 7093887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute leukemia in adults: assessment of remission induction with combination chemotherapy by clinical and cell-culture criteria.
    Curtis JE; Cowan DH; Bergsagel DE; Hasselback R; McCulloch EA
    Can Med Assoc J; 1975 Aug; 113(4):289-94. PubMed ID: 1056807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypocellular bone marrow with increased blasts.
    Gladson CL; Naeim F
    Am J Hematol; 1986 Jan; 21(1):15-22. PubMed ID: 3706286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aclacinomycin A and behenoyl arabinofuranosylcytosine combination chemotherapy for previously untreated acute leukemia.
    Sampi K; Sakurai M; Kaneko Y; Hattori M
    Oncology; 1986; 43(1):18-22. PubMed ID: 3455751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Glivec in combination with HA regimen for treatment of 20 patients with Ph chromosome positive acute leukemia].
    Meng FY; Zheng WY; Liu XL; Song LL; Xu B; Zhang Y; Huang F
    Ai Zheng; 2003 Aug; 22(8):840-3. PubMed ID: 12917031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and morphological features of cases of trisomy 13 in acute non-lymphocytic leukemia.
    Soni M; Brody J; Allen SL; Schulman P; Kolitz J; Rai K; Broome JD; Koduru PR
    Leukemia; 1996 Apr; 10(4):619-23. PubMed ID: 8618437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved remission induction rate with D-ZAPO but unimproved remission duration with addition of immunotherapy to chemotherapy in previously untreated children with ANLL.
    Baehner RL; Bernstein ID; Sather H; Higgins G; McCreadie S; Chard RL; Hammond D
    Med Pediatr Oncol; 1979; 7(2):127-39. PubMed ID: 291771
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.